Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.35
-0.0400-2.88%
Post-market: 1.350.0006+0.04%19:30 EDT
Volume:228.00K
Turnover:307.37K
Market Cap:81.91M
PE:-2.22
High:1.40
Open:1.40
Low:1.33
Close:1.39
52wk High:3.19
52wk Low:0.8700
Shares:60.67M
Float Shares:55.61M
Volume Ratio:0.79
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6085
EPS(LYR):-0.7000
ROE:-218.68%
ROA:-92.10%
PB:3.96
PE(LYR):-1.93

Loading ...

MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial

TIPRANKS
·
Jun 04

MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial

Reuters
·
Jun 04

Maia Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

THOMSON REUTERS
·
Jun 04

MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study

MT Newswires Live
·
Jun 03

MAIA Biotechnology receives FDA clearance for amendment to IND application

TIPRANKS
·
Jun 03

Maia Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 Thio-101 Trial Expansion

THOMSON REUTERS
·
Jun 03

MAIA Biotechnology announces open market purchases by CEO, director

TIPRANKS
·
Jun 02

Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)

TIPRANKS
·
Jun 02

MAIA says directors, officers hold 20.46% beneficial stake

Reuters
·
Jun 02

Maia Biotechnology Announces Open Market Purchases by CEO and Director

THOMSON REUTERS
·
Jun 02

Maia Biotechnology CEO Vlad Vitoc buys 72,700 common shares for $100,870.29

Reuters
·
Jun 02

Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200

Reuters
·
Jun 02

Maia Bio CSO Sergei Gryaznov acquires 2,000 common shares worth $2,690

Reuters
·
Jun 02

Maia Biotech presents Phase 3 THIO-104 trial design for ateganosine in checkpoint-resistant lung cancer at ASCO 2026

Reuters
·
Jun 01

Maia Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

THOMSON REUTERS
·
Jun 01

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

GlobeNewswire
·
Jun 01

MAIA Biotechnology Shareholders Back Board and Auditor Appointments

TIPRANKS
·
May 22

Maia Biotechnology shareholders ratify Grant Thornton as 2026 auditor

Reuters
·
May 22

MAIA Biotechnology Ends ATM Stock Offering Agreement

TIPRANKS
·
May 15

Maia Biotechnology Inc - Sold 3.1 Mln Shares for Gross Proceeds of $5.7 Mln Under Sales Agreement - SEC Filing

THOMSON REUTERS
·
May 15